August 17–21, 2025, Washington, DC, USA - Visit us at Booth 2230.
Read More
Email:
Phone:
Toggle navigation
Home
Services
ADC Linker Development
Chemically Cleavable Linker
Acid Cleavable Linker/Hydrazone Linker
Disulfide Linker
Enzyme Cleavable Linker
Cathepsin B Cleavable Linker/Peptide Linker
Phosphatase Cleavable Linker
Sulfatase Cleavable Linker
β-Galactosidase Cleavable Linker
β-Glucuronidases Cleavable Linker
Non-Cleavable Linker
ADC Payload Development
Biological Payload
Chemical Payload
Nanocarrier
Protein Toxin
ADC Manufacturing
ADC cGMP Manufacturing
ADC Fill/Finish
ADC Formulation Development
ADC Purification
ADC Linker–Payload Conjugation
Calicheamicin-Based Linker Conjugation
Deruxtecan-Based Linker Conjugation
MMAE/MMAF-Based Linker Conjugation
PBD-Based Linker Conjugation
SN-38-Based Linker Conjugation
Antibody Modification and Conjugation
Bispecific Antibody Conjugation
Carbohydrate Conjugation
Click Chemistry Conjugation
Cysteine Conjugation
Enzymatic Conjugation
Lysine Conjugation
Non-natural Amino Acids Conjugation
Site-Specific Conjugation
Thio-engineered Antibody
Tyrosine Conjugation
ADC Analysis and Characterization
In Vitro
Analysis
In Vivo
Analysis
ADC Bioanalysis
ADC Bioassay
ADME Analysis
DMPK Analysis
Drug Distribution Analysis
Drug-to-Antibody Ratio Analysis
Stability Analysis
ADC Development Platform
Antibody Fragment-Drug Conjugates (FDCs)
Bispecific Antibody-Drug Conjugates (BsADCs)
Degrader-Antibody Conjugates (DACs)
Dual-Payload Antibody–Drug Conjugates
Nanobody-Drug Conjugates (NDCs)
Scaffold-Drug Conjugates (SDCs)
Products
ADC Cytotoxin
Auristatins
Calicheamicins
Camptothecins
Daunorubicins/Doxorubicins
Duocarmycins
Maytansinoids
Piericidins
Pyrrolobenzodiazepines
Traditional Cytotoxic Agents
Other Cytotoxins
ADC Cytotoxin with Linker
ADC Linker
Cleavable Linker
Non-Cleavable Linker
Antibody-Drug Conjugates (ADCs)
Targets
AXL Targets
BCMA Targets
CD19 Targets
CD22 Targets
CD30 Targets
CD33 Targets
CD79b Targets
c-MET Targets
EGFR Targets
FOLR1 Targets
HER2 Targets
Nectin-4 Targets
ROR1 Targets
TF Targets
TROP-2 Targets
Solutions
Early Discovery
Process Development
Preclinical Studies
Resource
Frequently Asked Questions
News
Scientific Corner
Support Documents
Company
Contact Us
About Us
Careers
Inquiry
News
Home
Resource
News
News
Analyzing the Impact of ADCs on Ovarian Cancer Treatment
Navigating the ADC Market: Opportunities and Challenges
Targeted Therapy with ADCs: A Focus on Trop-2 Antibody-Drug Conjugates
The Evolution of ADCs: From First Generation to Next-Gen Innovations
The Role of Bispecific ADCs in Modern Immunotherapy
Antibody-Drug Conjugates for Prostate Cancer
Current ADC Linker Chemistry
SPDB Linkers in Antibody-Drug Conjugates
Val-Cit Linkers in Antibody-Drug Conjugates
Microtubules: Definition, Structure, Function and Inhibitors
Site-Specific Conjugation for Antibody-Drug Conjugates (ADCs)
Camptothecin: Definition, Structure, and Mechanism of Action
Antibody-Drug Conjugates with Dual Payloads
Application of Click Chemistry in the Next Generation of Novel Antibody Drug Conjugation (ADCs)
Bispecific Antibodies and Bispecific Antibody ADCs
Bystander Effect of Antibody-Drug Conjugates (ADCs)
Challenges in ADC Neutralizing Anti-Drug Antibody (NAb) Detection
Characteristics of Ideal ADC Payloads
Clinical Pharmacology of Antibody-Drug Conjugates
Cytotoxic payloads in ADCs
Cytotoxins: Definition, Function, Classification and Mechanism of Action
Degrader-Antibody Conjugates (DAC): Novel PROTAC-ADC Conjugation Strategies
Disitamab Vedotin for the treatment of urothelial cancer was approved by the US FDA
Doxorubicin: Definition, Structure, Cardiotoxicity, Applications and Mechanism of Action
Drug Conjugates: Latest Research Progress
Drug-to-Antibody Ratio (DAR) Characterization of Antibody Drug Conjugation (ADCs)
Exatecan mesylate: a novel topoisomerase I inhibitor in ADC technolog
Kadcyla - The Most Commercially Successful ADC
Maytansine And Its Analogues
Nanobodies: Definition, Structure, Advantages and Applications
New medicine for lymphoma! Antibody-Drug Conjugate (ADC) loncastuximab tesirine (Lonca) applies for listing!
Overview of ADC Combination Therapies
Quantitative Analysis of ADC Components - Ligand Binding Assay (LBA) and LC-MS/MS
Review of ADC bioconjugation technology and research progress
Review of ADC linker and research progress
Review of ADC payload and research progress
Review of FDA-Approved ADC Drugs up to 2024
Studies have shown that thapsigargin has anti-COVID-19 virus (SARS-CoV-2) activity
TF-targeted antibody-drug conjugate (ADC) tisotumab vedotin shows strong efficacy and will be applied marketing
The development history of ADC drugs
Tivdak - The First FDA-Approved Tissue Factor-Targeted ADC
Tubulin Inhibitors - Highly Potential ADC Payloads
Two New Structures Resolved Unstable Maleimide Linkers in ADCs
What are Antibody Drug Conjugates?
What are Protein Toxins and Their Applications in ADCs
What are the Targets for ADC Therapy in Breast Cancer?
What is Bioconjugation? - Antibody Conjugation & Drug Conjugation
What is Calicheamicin?
What is Monomethyl Auristatin E (MMAE)?
What is Monomethyl Auristatin F (MMAF)?
What is Pyrrolobenzodiazepine (PBD)?
With rich potential, ADC drugs are expected to continue to broaden the scope of tumor treatment
Antibody-Drug Conjugates in Clinical Trials
ADC Transactions Flourish - UP to 10 Billion
Adcetris for Hodgkin's Lymphoma
Antibody-Drug Conjugate Immunotherapy
Antibody-Drug Conjugates for Brain Cancer
Antibody-Drug Conjugates for Lung Cancer
Biotinylation Reagents in Antibody-Drug Conjugates
Click Chemistry in Antibody Drug Conjugates
Disulfide Linkers in Antibody-Drug Conjugates
Elahere for Ovarian Cancer Treatment
Maleimide Linkers in Antibody-Drug Conjugates
PEG Linkers in Antibody-Drug Conjugates
Peptide Linkers in Antibody-Drug Conjugates
Trodelvy for Breast Cancer Treatment
*
Only for research. Not suitable for any diagnostic or therapeutic use.
Inquiry Basket
Loading ......
Delete selected
Go to checkout
